Continuous Glucose Monitoring for Type 2 Diabetes

(Cyber GEMS Trial)

Overseen By Fortmann Addie, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Scripps Whittier Diabetes Institute

Disqualifiers: Icu placement, Pregnancy, Others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: During hospitalization

554 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method to manage blood sugar levels in hospitalized patients with Type 2 Diabetes using a continuous glucose monitoring (CGM) system. The aim is to determine if this system, which tracks blood sugar in real-time, can help healthcare teams quickly adjust treatments and prevent dangerous drops in blood sugar. Participants will either use the Dexcom G6 CGM system or follow usual care, which involves regular blood sugar checks. Individuals with Type 2 Diabetes, who are on insulin, or have recently experienced high blood sugar levels might be suitable for this trial. As an unphased trial, this study offers participants the chance to contribute to innovative diabetes care solutions.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this continuous glucose monitoring system is safe for hospital use?

Research has shown that the Dexcom G6 Continuous Glucose Monitoring (CGM) system is generally safe to use. Studies have found that it can help people with type 2 diabetes manage their blood sugar levels more effectively. For instance, one study demonstrated that using a CGM like the Dexcom G6 improved blood sugar control and reduced heart health risks in patients not using insulin.

Another study tested the Dexcom G6 during simulated medical procedures and found it performed well, indicating reliability in various medical situations. While no treatment is without risk, most users tolerate the Dexcom G6 well. The FDA has already approved it for managing diabetes, supporting its safety.

Joining a trial with this device means using a proven system that has helped many people manage diabetes more effectively. However, discussing personal safety and health needs with a healthcare provider before joining any trial is always important. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the Continuous Glucose Monitoring (CGM) approach for managing Type 2 Diabetes because it offers real-time insights into blood sugar levels, unlike traditional fingerstick or point-of-care (POC) testing. The Dexcom G6 CGM system provides continuous data, which allows for more precise and timely adjustments in insulin therapy. This could lead to better glucose control and potentially reduce complications associated with Type 2 Diabetes. Additionally, the capability for remote monitoring and management helps streamline patient care, making it more convenient and potentially more effective than current standard practices.

What evidence suggests that this trial's treatments could be effective for managing Type 2 Diabetes?

Studies have shown that the Dexcom G6 Continuous Glucose Monitoring system can greatly improve blood sugar control in people with type 2 diabetes. In this trial, participants in the Continuous Glucose Monitoring arm will use the Dexcom G6 system, which has been linked to a significant drop in HbA1c levels, an important measure of average blood sugar over time. One study reported a decrease of about 2.4% in HbA1c after six months of use. Additionally, patients spent more time with their blood sugar levels in a healthy range and less time with dangerously high levels. These findings suggest that the Dexcom G6 can effectively help manage diabetes by keeping blood sugar levels stable. Meanwhile, participants in the Usual Care arm will have their glucose monitored via the hospital's standard POC testing protocol, with CGM data used for evaluation purposes only. ^{1 3 6 7 8}

Who Is on the Research Team?

Athena Philis-Tsimikas, MD

Principal Investigator

Scripps Whittier Diabetes Institute

Addie Fortmann, PhD

Principal Investigator

Scripps Whittier Diabetes Institute

Are You a Good Fit for This Trial?

This trial is for hospitalized individuals with Type 2 Diabetes who have high blood sugar levels or are on insulin. They must have a documented diagnosis of diabetes or an HbA1c level of at least 6.5%. Exclusions include current research study participants, short hospital stays, ICU patients, adhesive allergies, non-English/Spanish speakers, and pregnancy.

Inclusion Criteria

I have been diagnosed with Type 2 Diabetes or my HbA1c level was at least 6.5% in the last 90 days.

I use insulin injections or have had high blood sugar levels recently.

Exclusion Criteria

Anticipated length of stay < 24 hours

The study's lead investigator or your doctor thinks that you have a condition that makes it unsafe for you to participate in the study.

I am currently in or expected to be in the ICU.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive continuous glucose monitoring using the Dexcom G6 device, with data transmitted for real-time management and clinical optimization.

During hospitalization

Continuous monitoring during hospital stay

Follow-up

Participants are monitored for safety and effectiveness after treatment, including post-CGM satisfaction survey and data analysis.

Up to 2 weeks following discharge

Data Analysis

CGM data is downloaded and analyzed to assess glucose variability, infection rates, and other clinical outcomes.

Immediately following intervention completion

What Are the Treatments Tested in This Trial?

Interventions

• Dexcom G6 Continous Glucose Monitoring Management
• Usual Care - Blinded Continuous Glucose Monitoring Management

Trial Overview The Cyber GEMS trial tests a new continuous glucose monitoring (CGM) system against usual care in hospitals. It aims to improve blood sugar management using a digital dashboard for real-time remote patient monitoring and prioritization for interventions.

How Is the Trial Designed?

Group I: Continuous Glucose Monitoring Experimental Treatment 1 Intervention

Research Assistants (RAs) will verbally administer baseline survey and insert Dexcom G6 CGM, before unveiling the group assignment. CGM data will be transmitted from bedside iPhone to web-based platforms for: (1) Real-Time Management (via iPad-based FOLLOW app used by bedside RN and Digital Dashboard used by remote monitoring team) and (2) Clinical Optimization (via CLARITY, a Diabetes RN Coordinator will conduct remote clinical management of patients from a central, Scripps Diabetes Hub). A post-CGM satisfaction survey will be administered and compensation provided when CGM is removed prior to discharge or within 2 weeks following discharge. The CGM readings will be used to make recommendations for insulin adjustment and glucose management. After discharge, CGM data will be downloaded from a HIPPA-compliant, web-based CGM data management tool, and saved in Excel. The Data Analyst, blinded to condition, will routinely screen CGM data and merge individual spreadsheets for analysis.

Group II: Usual Care Active Control 1 Intervention

RAs will verbally administer a baseline survey and insert the Dexcom G6 CGM. before unveiling the group assignment. CGM data will be blinded and used for evaluation purposes only. Glucose will be monitored via the hospital's standard POC testing protocol (i.e., prior to meals and at bedtime for patients who are eating, and every 4-6 waking hours if not eating). Glucose management in UC is designed to minimize differences between groups, aside from CGM monitoring, A post-CGM satisfaction survey will be administered and compensation provided when the CGM is removed prior to discharge or within 2 weeks following discharge. After discharge, CGM data will be downloaded from a HIPPA-compliant, web-based CGM data management tool, and saved in individual Excel spreadsheets. The study Data Analyst, blinded to study condition, will routinely screen CGM data and merge individual spreadsheets for analysis.

Who Is Running the Clinical Trial?

Scripps Whittier Diabetes Institute

Lead Sponsor

Trials

19

Recruited

5,400+

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Trials

2,513

Recruited

4,366,000+

Published Research Related to This Trial

In a real-world setting, the blinded Dexcom G6 Pro continuous glucose monitor (CGM) demonstrated a mean absolute relative difference (MARD) of 11.0% over a median wear time of 50 hours, indicating reliable accuracy for glucose monitoring in individuals with type 1 diabetes.

The accuracy of the Dexcom G6 Pro improved after the first 12 hours of use, stabilizing at around 10.1% MARD thereafter, which aligns with previous laboratory-based accuracy findings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Testing the Real-World Accuracy of the Dexcom G6 Pro CGM During the Insulin-Only Bionic Pancreas Pivotal Trial. Marak, MC., Calhoun, P., Damiano, ER., et al.[2023]

In a study involving 11 patients with type 1 diabetes, the Dexcom G5 Mobile (DG5) continuous glucose monitor demonstrated significantly better accuracy than the Eversense (EVS) implantable sensor during controlled clinical conditions, particularly when blood glucose levels were decreasing.

While both devices showed similar accuracy during home monitoring, DG5 had a lower median absolute relative difference (ARD) of 7.91% compared to EVS's 11.4% during glucose excursions in a clinical setting, indicating it may be more reliable for detecting rapid changes in glucose levels.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparing the accuracy of transcutaneous sensor and 90-day implantable glucose sensor. Boscari, F., Vettoretti, M., Amato, AML., et al.[2021]

The Dexcom G6 continuous glucose monitoring (CGM) system demonstrated a mean absolute relative difference (MARD) of 7.7% in accuracy when compared to laboratory blood glucose measurements, indicating high reliability for monitoring glucose levels in children and adolescents with type 1 diabetes.

With 96.2% of estimated glucose values falling within 20% of the reference values, the G6 system's accuracy supports its potential to enhance glycemic control and encourage consistent use among young patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Performance of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System in Pediatric Participants With Type 1 Diabetes. Welsh, JB., Zhang, X., Puhr, SA., et al.[2020]

The Dexcom G6 continuous glucose monitoring system maintained its functionality and data integrity after exposure to simulated x-ray and MRI procedures, indicating it is safe to use during these medical imaging processes.

During MRI simulations, the devices experienced minimal displacement force, heating of less than 2°C, and low induced currents, suggesting they are unlikely to be dislodged or damaged during standard MRI scans.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and Functional Integrity of Continuous Glucose Monitoring Components After Simulated Radiologic Procedures. Thomas, C., Welsh, JB., Lu, S., et al.[2021]

In a study involving 34 adults with type 1 diabetes, the Guardian, Navigator, and Glucoday continuous glucose monitors (CGMs) showed comparable numerical accuracy, particularly excelling in hypoglycemic conditions, while the DexCom had significantly larger numerical errors.

Clinical accuracy during euglycemia was high for all CGMs, but the Navigator and Glucoday performed better in detecting hypoglycemia, indicating their potential for better patient safety in critical situations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Kovatchev, B., Anderson, S., Heinemann, L., et al.[2022]

Regularly reviewing weekly continuous glucose monitoring (CGM) reports is linked to improved quality of life (QoL) and glycemic outcomes in adults with diabetes, with 73.1% reporting better A1C levels and 75.9% feeling more confident about managing hypoglycemia.

Engaging with the report, especially by discussing it with family or friends, positively impacts QoL and perceived glycemic control, while doing nothing with the report's information is associated with poorer glycemic control.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The Role of Retrospective Data Review in the Personal Use of Real-Time Continuous Glucose Monitoring: Perceived Impact on Quality of Life and Health Outcomes. Polonsky, WH., Soriano, EC., Fortmann, AL.[2022]

The FDA is considering a nonadjunctive label claim for the DEXCOM G5 Mobile continuous glucose monitoring (CGM) system, which would allow users to make insulin dosing decisions based solely on CGM data without needing confirmatory blood glucose tests.

If approved, this change could enhance diabetes management by providing real-time glucose readings every 5 minutes, along with alerts and trending information, potentially reducing the risk of hypoglycemia and improving overall patient care.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Regulation Catches Up to Reality. Edelman, SV.[2019]

In 2022, there were 281,963 reported adverse events related to continuous glucose monitors (CGMs), highlighting a significant safety concern for people with diabetes.

The analysis of adverse events for four CGM products revealed that common issues included inaccuracy and device malfunctions, indicating a need for improved monitoring and device reliability to enhance user experience.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adverse Event Causes From 2022 for Four Continuous Glucose Monitors. Krouwer, JS.[2023]

A study of 47,784 users of the Dexcom G6 continuous glucose monitoring system over 6 months found that more than 75% of users across various regions utilized alert features, which significantly improved glycaemic control.

Enabling Low and Urgent Low Soon alerts was linked to less time spent below target glucose levels, while High alerts were associated with more time in the target range and less time above it, indicating that proper use of these alerts can enhance diabetes management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

G6 continuous glucose monitoring system feature use and its associations with glycaemia in Europe. Acciaroli, G., Parkin, CG., Thomas, R., et al.[2023]

Continuous glucose monitors (CGMs) have been associated with over 25,000 complaints of sensor inaccuracy reported to the FDA since 2015, highlighting significant safety concerns regarding their reliability for insulin dosing.

Despite evidence of sporadic and unpredictable errors in CGMs, the FDA approved the Dexcom G5 for nonadjunctive use, indicating a need for improved safety procedures rather than removing existing safeguards.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Nonadjunctive Use of Continuous Glucose Monitors for Insulin Dosing: Is It Safe? Shapiro, AR.[2018]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11929555/

Clinical outcomes of a real‐world prospective study using ... In this study, significant reductions in mean HbA1c without hypoglycaemia were observed in both T1D and T2D groups following Dexcom ONE use, ...

2. provider.dexcom.com provider.dexcom.com/dexcom-community-glucose-monitoring-project-six-month-results-using-continuous-glucose-monitoring-0

Six-Month Results Using Continuous Glucose Monitoring ... Participants using a glucose sensor (n=237) showed clinically meaningful and statistically significant (p<0.001) decrease in A1C of 2.4%+1.9% at 6 months.

3. diabetesjournals.org diabetesjournals.org/clinical/article/42/4/540/157065/The-Dexcom-Community-Glucose-Monitoring-Project-6

The Dexcom Community Glucose Monitoring Project: 6-Month ... After 6 months of program participation, mean A1C decreased by 2.4 ± 1.9% from baseline to 6-month follow-up (from 9.4 ± 1.7 to 7.1 ± 1.2%, P <0.001).

4. nature.com nature.com/articles/s41598-024-83548-4

Continuous glucose monitoring among adults with type 2 ... Patients showed improvements in time in range (39.7–61.9%, p < 0.0001), time > 180 mg/dL (60.1–37.9%, p < 0.001), time > 250 mg/dL (27.6–8.5%, p ...

5. dom-pubs.onlinelibrary.wiley.com dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.70008

Continuous glucose monitoring in noninsulin‐treated type 2 ... In a study of 47 non-insulin users, Reed et al. found that 3 months of G6 use was associated with significant decreases in mean HbA1c (8.4%–6.9 ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC8252147/

Safety and Functional Integrity of Continuous Glucose ... We investigated wearable components of the Dexcom G6 continuous glucose monitoring (CGM) System in simulated therapeutic and diagnostic radiologic procedures.

7. dom-pubs.onlinelibrary.wiley.com dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15608

Continuous glucose monitoring for glycaemic control and ... Dexcom G6 CGM was associated with improved glycaemic control and cardiometabolic risk in patients with T2DM who were not on insulin.

8. sciencedirect.com sciencedirect.com/science/article/pii/S1871402125001006

Does the short-term use of continuous glucose monitoring ... We found Continuous Glucose Monitoring can significantly improve diabetes self-management behaviour and quality of life. •. Improvements reduced when Continuous ...